Kamlanoflast for active ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug called kamlanoflast for people with ALS whose disease is actively progressing. It aims to see if the drug can slow down the disease by reducing inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of ALS (possible, probable, or definite) by a doctor using standard criteria.
- You should be between 18 and 75 years old.
- Your muscle weakness must have started within the last 3 years.
- Your ALS must be progressing at a certain rate (at least half a point per month on the ALS functional rating scale).
- A blood test must show a high level of a nerve protein called neurofilament light chain (NfL) – at least twice the normal level for your age.
- You need to have good enough lung function (slow vital capacity over 65% of expected) and be able to swallow pills or have a feeding tube.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests a nasal spray medication called foralumab to see if it is safe and affects inflammation in the brain for people with ALS. It may help by calming overactive immune cells in the nervous system.
This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This trial tests a new medicine called LY4256984 for people with sporadic ALS (ALS not caused by a known genetic mutation). The goal is to see if the drug is safe and how it affects the body. It may offer a new treatment option for people recently diagnosed with ALS.
This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.
Hear when a new Neuro-Degenerative Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.